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iNeuroscience Research Laboratory, Faculty of Health Sciences, Pontificia Universidad Catolica Madre y
Maestra, Santiago de los Caballeros, República Dominicana
jBanco Nacional de Cerebros-UNPHU, Universidad Nacional Pedro Henrı́quez Ureña, República Dominicana
Handling Editor: Jesús Ávila
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Abstract.
Background: Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP) are examples of neurodegenerative dis-
eases, characterized by abnormal tau inclusions, that are called tauopathies. AD is characterized by highly insoluble paired
helical filaments (PHFs) composed of tau with abnormal post-translational modifications. PSP is a neurodegenerative disease
with pathological and clinical heterogeneity. There are six tau isoforms expressed in the adult human brain, with repeated
microtubule-binding domains of three (3R) or four (4R) repeats. In AD, the 4R:3R ratio is 1:1. In PSP, the 4R isoform
predominates. The lesions in PSP brains contain phosphorylated tau aggregates in both neurons and glial cells.
Objective: Our objective was to evaluate and compare the processing of pathological tau in PSP and AD.
Methods: Double and triple immunofluorescent labeling with antibodies to specific post-translational tau modifications
(phosphorylation, truncation, and conformational changes) and thiazin red (TR) staining were carried out and analyzed by
confocal microscopy.
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Results: Our results showed that PSP was characterized by phosphorylated tau in neurofibrillary tangles (NFTs) and glial
cells. Tau truncated at either Glu391 or Asp421 was not observed. Extracellular NFTs (eNFTs) and glial cells in PSP exhibited
a strong affinity for TR in the absence of intact or phosphorylated tau.
Conclusion: Phosphorylated tau was as abundant in PSP as in AD. The development of eNFTs from both glial cells and
neuronal bodies suggests that truncated tau species, different from those observed in AD, could be present in PSP. Additional
studies on truncated tau within PSP lesions could improve our understanding of the pathological processing of tau and help
identify a discriminatory biomarker for AD and PSP.
Keyword: Alzheimer’s disease, neurofibrillary tangle, progressive supranuclear palsy, tau protein, truncation
INTRODUCTION
Progressive supranuclear palsy (PSP) is a neu-
rodegenerative disease [1] first described by Steele
and colleagues in 1964 [2]. PSP is characterized by
onset over 40 years of age, with a mean survival of
patients from symptom onset of six years, and culmi-
nation in the death of patients. It belongs to a group
of over 20 disorders that are termed tauopathies, of
which Alzheimer’s disease (AD) is the most com-
mon [3]. PSP presents a wide variety of signs and
symptoms that can overlap with other neurodegen-
erative disorders [4]. PSP affects movement, control
of walking (gait) and balance, speech, swallowing,
and vision (blurring of vision and problems con-
trolling eye movement). People with PSP may also
exhibit parkinsonism, photophobia, disturbances of
sleep and emotions, depression, anxiety, and demen-
tia [1, 5–7]. PSP has a prevalence of 5–8/100,000
individuals [8, 9], but the clinical diagnosis can only
be confirmed by postmortem pathological analysis.
PSP brain exhibits significant atrophy in the brain
convolutions, brain stem, basal ganglia (substantia
nigra, subthalamic nucleus, and globus pallidus),
cerebral cortex (frontal lobe), dentate nucleus of the
cerebellum, and spinal cord. Tau protein is patholog-
ically modified and forms aggregates in neuronal and
glial bodies in PSP [10]. Under normal conditions, tau
stabilizes the microtubules favoring the movement of
vesicles and organelles along the axon.
Tau undergoes cycles of phosphoryla-
tion/dephosphorylation to carry out its function. Six
isoforms of tau are expressed in the adult human
brain, which results from alternative splicing of pre-
mRNA generated from a single, MAPT gene. These
isoforms (ranging from 352 to 441 amino acids in
length) differ in the presence of N-terminal inserts
(0, 1, or 2) and the number of C-terminal repeats (3R
or 4R). The microtubule-binding region (MTBR) is
composed of either 3 or 4 repeats. Whereas the ratio
of 3R and 4R isoforms is 1:1 in the healthy brain,
there are many 4R isoforms in PSP disease [11].
PSP is a sporadic onset disease with a few cases
of familial origin associated with mutations in the
MAPT gene [12]. These mutations are not exclusive
to PSP and can occur in other neurodegenerative
disorders. The cause of the onset of PSP pathology
is still unknown. It has been suggested that altered
mitochondrial function involved in neurodegenera-
tion could occur at the beginning of PSP. Most of
the current studies are focused on the relationship
of the tau protein with neuronal and glial cell death.
Tau post-translational modifications, including
acylation, O-GlcNAcylation, O-glycosylation, and
truncation, have been related to neurodegeneration.
These modifications lead to tau accumulation in the
neuronal soma (pre-neurofibrillary tangles (NFT)
and NFT), oligodendrocytes (coiled body), glial
cells (tuft-shaped astrocytes, TAs), and neuronal
processes (neuropil threads) [13]. In PSP, the
neuropathological changes do not correlate with
the patient deterioration. However, the presence of
the lesions in different brain areas exemplifies the
phenotypic variability [14]. Soluble and insoluble
pathological tau is found in the cell soma in a toxic
form, affecting neuronal and glial cells.
The particular sequence of the pathological tau
processing has been derived from studies using spe-
cific immunological markers in AD. In this work, we
have compared post-translational changes in tau pro-
tein in NFTs and glial cells in PSP and AD brains.
We have used a panel of antibodies that recognize
different aspects of tau protein in order to understand
the differing states of tau protein during aggregation
and NFT development in the two disorders.
MATERIALS AND METHODS
PSP brains
The striatum, amygdala, and hippocampus from
PSP brains were obtained from the Brain Bank of the
Institute of Neuropathology of Bellvitge University
Hospital, Barcelona, Spain. The age range of brain
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donors was from 57 to 86 years old (Table 3). The
diagnosis was confirmed by histopathological analy-
sis. Formalin-fixed paraffin-embedded tissue blocks
were cut into 6-m thick sections and mounted on
glass slides for further processing.
AD brains
Human brain tissue from six AD patients (age
range 47 to 90 years, mean of 67.5 years, and
with 2–6 h postmortem delay) was used (Table 3).
Tissue was obtained from the National Demen-
tia BioBank, Mexico, following the institutional
bioethics guidelines. The diagnosis of AD followed
the NIA-NINCDS group criteria [15]. Blocks of the
hippocampus and adjacent entorhinal cortex were
fixed by immersion in a solution of 4% paraformalde-
hyde in phosphate-buffered saline (PBS), pH 7.4, at
4◦C, for seven days. The pathological severity of AD
was determined by the density of NFTs and neuritic
plaques, using the immunoperoxidase technique and
thiazine red (TR) staining.
Immunofluorescent labeling
Tissue slices were deparaffinized in xylene and
then rehydrated in serial solutions of ethanol and
distilled water. Antigen retrieval was achieved by
treatment at 100◦C for 20 min in citrate buffer (0.1 M
citric acid, 0.1 M sodium citrate, pH 6.0). Lipofus-
cin autofluorescence was removed with Sudan B
Black (SBB) solution (0.1% SBB in 70% ethanol)
for 15 min. Non-specific sites were blocked with 10%
fetal bovine serum in PBS for 20 min at room temper-
ature. Tissues were then incubated with the primary
Table 2
List of secondary antibodies used in this study. Antibody-specific
fractions were used to avoid cross-reaction between antibodies.
Mo, mouse; Rb, rabbit
Fluorescent Conjugate Isotype
Alexa488 Goat anti-Mo IgG ()
Goat anti-Mo IgM ()
Goat anti-Rb IgG (H + L)
Alexa546 Goat anti-Mo IgG ()
Goat anti-Mo IgM ()
Goat anti-Rb IgG (H + L)
CY5 Goat anti-Mo IgG ()
Goat anti-Mo IgM ()
Goat anti-Rb IgG (H + L)
antibody cocktail (Table 1) overnight at 4◦C, and
then with the secondary antibodies (Table 2). Sec-
tions were counterstained with TR to differentiate
non-fibrillar and fibrillar tau aggregates [16, 17] and
mounted in Immuno-Flour mounting medium (ICN
Biomedicals, Aurora, OH).
Confocal microscopy
Double and triple-immunolabeled sections were
examined using a confocal laser scanning micro-
scope (TCS-SP8, Leica, Heidelberg), and a 100x
oil-immersion plan Apochromatic objective (NA
1.4). Ten to fifteen consecutive individual sections
were sequentially scanned at 0.5–0.8 m intervals
for two or three channels throughout the z-axis of
the sample. The collected images were projected and
analyzed onto the two-dimensional plane using a
pseudocolor display of green (FITC), red (TRITC),
and blue (CY5). Fluorochromes were excited at
488 nm (for FITC), 540 nm (for TRITC), and 650 nm
(for CY5).
Table 1
List of primary antibodies used in this study. The antibodies recognize different tau epitopes
including phosphorylation sites, conformational changes, and truncated species
Primary antibody Epitope Isotype Reference or
source
499 Intact tau at 14–26 Mo IgG [52]
Tau7 Intact tau at 426–441 Mo IgG [38]
pT231 Phosphorylation at Thr231 Rb IgG Invitrogen
AT8 Phosphorylation at Ser202, Thr205 Mo IgG Invitrogen
TG3 Regional conformational change, dependent on
phosphorylation at Thr231, Ser235
Mo IgM [53]
AT100 Regional conformational change, dependent on
phosphorylation at Thr212, Ser214
Mo IgG Invitrogen
Alz50 Amino acids: 5–15, 312–322 Mo IgM [44, 54]
Structural conformational change
pS396 Phosphorylation at Ser396 Rb IgG Invitrogen
PHF1 Phosphorylation at Ser396, Ser404 Mo IgG [55]
TauC3 Truncation at Asp421 Mo IgG [38]
423 Truncation at Glu391 Mo IgG [34]
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Table 3
Cases used in this study
Diagnosis Sex Age Brain bank
Progressive
supranuclear palsy
























The pathological processing of the tau pro-
tein occurs in a wide variety of diseases called
tauopathies, including AD and PSP. Identifying
similarities and differences in the pathological
tau processing can favor the understanding of
tauopathies and, hopefully, the finding of an appro-
priate biomarker and treatment.
Neuropathology of AD
Macroscopically, AD brain showed a considerable
reduction in the brain volume (Fig. 1B) compared
to a control case (Fig. 1A). Aside from enlargement
of the sulci and ventricles, hippocampal atrophy is
prominent in AD (Fig. 1B).
Histopathological lesions in AD
In AD, the characteristic histopathological lesions
are the neuritic plaques and NFTs (Fig. 2). Neu-
ritic plaques comprise a dense core surrounded
by a diffuse corona of amyloid- peptide (A)
(Fig. 2A; arrowheads), and numerous dystrophic
neurites (DNs) (Fig. 2A; arrows). Neuritic plaques
showed colocalization of the antibodies pT231 (green
channel) and TG-3 (blue channel), with TR (red chan-
nel). TR is a fluorescent marker with an affinity for the
insoluble filaments of A and tau, in neuritic plaques
and NFTs, respectively [16, 17]. Fibrillar TR-positive
A aggregates were commonly observed in blood
vessels (Fig. 2B; large arrows). NFTs positive for all
three markers (pT231/TG-3/TR) were found in the
Fig. 1. Coronal section of a healthy (left) and AD hemisphere
(right). In AD, a considerable reduction in the brain volume with
enlargement of the grooves between folds, prominent ventricles
(V), and hippocampal atrophy (arrows) was observed.
periphery (Fig. 2B; small arrows). Neuropil threads
and DNs were observed with a variable extent of
colocalization for these markers. Aggregation of tau
protein in the neuronal soma was also seen as diffuse
granular staining called pre-NFTs (Fig. 2C; arrows).
Pre-NFTs frequently showed dense granular perinu-
clear staining (Fig. 2C; arrowhead), immunoreactive
with pT231 antibody (green channel), and colocaliz-
ing with the Alz50 antibody (blue channel). Pre-NFTs
did not show an affinity for the TR dye. In a more
advanced stage, pre-NFTs were distinguished in the
periphery as small aggregates immunoreactive with
these markers (Fig. 2C; small arrows). These first
dense aggregates are referred to as small NFTs. They
are observed in Fig. 2D, where colocalization of
TG-3 and TR was observed (Fig. 2D; arrows). DNs
with varying degrees of colocalization were found in
the neighborhood. Intracellular NFTs (iNFTs) were
flame-shaped (Fig. 2E; arrows) and recognized by TR
and the antibody 423 (blue channel). Autofluorescent
lipofuscin granules were observed in the rhodamine
channel (*). The S199 antibody strongly recog-
nized some DNs in the vicinity. Extracellular NFTs
(eNFTs; Fig. 2F; arrows) were reactive with only anti-
body 423 (blue channel), that was colocalized with
TR to varying extents. S199 antibody-positive DNs
were detected in the periphery.
Neuropathological anatomy in PSP
Macroscopically, coronal sections at the level of
the subthalamic nucleus showed that there was atro-
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Fig. 2. Characteristic lesions in AD. A) Neuritic plaques (NPs) bound thiazine red (TR). Associated with NPs, dystrophic neurites (DNs)
(arrows) were immunoreactive with both pT231 (green channel) and TG3 (blue channel) antibodies, and these demonstrated varying extents
of colocalization. B) Amyloid angiopathy. A blood vessel (BV) was labeled with TR (arrows). Many DNs and neurofibrillary tangles (NFTs)
were observed at the proximity of the BV, and these showed colocalization with pT231/TG3/TR to varying extents. C-F) Aggregation pattern
of tau in the neuronal soma. C) The pre-NFTs were characterized by diffuse granular staining with RZ3 and Alz50 (arrow). Perinuclear
staining (arrowhead) with no affinity for TR was also observed. Small dense tau aggregates (arrowheads) were observed in the vicinity of
pre-NFTs. D) Small NFTs was recognized by pT231 and strongly colocalized with TR (arrows). E) Intracellular NFTs (iNFTs) recognized
only by TR and colocalizing with the antibody 423; fibers tended to be compact (arrows). S199-reactive DNs were observed. F) Extracellular
NFTs (eNFTs) showed immunoreactivity mainly with antibody 423 but with partial colocalization with TR. The eNFTs are a loose structure
(arrows). Images obtained with the Leica SP8 Confocal Microscope. *Lipofuscin: autofluorescent granular structures. Scale bars, 10 m,
except for (B), 50 m.
phy of the globus pallidus and subthalamic nucleus
(Fig. 3A; arrowhead) in PSP brain. The hippocam-
pus showed considerable atrophy in advanced stages
(Fig. 3A; small arrow) and ventricles appeared
enlarged (Fig 3A; V). The midbrain showed tegmen-
tal atrophy and loss of pigmentation in the substantia
nigra (not shown). The locus coeruleus showed a rel-
atively preserved pigmentation in the pontine section.
The cerebellum presented with atrophy in the dentate
nucleus (not shown).
Tau pathology in PSP
In PSP, the histopathological lesions are char-
acterized by hyperphosphorylated tau aggregates
predominantly of the 4R isoform. These aggregates
are found in neurons, glial cells, and oligodendro-
cytes [18]. Fibrillar tau aggregates in TAs bound TR
dye and were phosphorylated at both AT8 (green
channel) and pS396 sites (Fig. 4A; arrows). This
staining of small fibrils is called pre-NFT in PSP
(Fig. 4A;*). Phosphorylated tau was expressed as
Fig. 3. PSP coronal brain section of the brain stem shows discrete
frontotemporal atrophy, quadrigeminal cistern atrophy, and sieve
state in frontal periventricular white matter, and thalamus.
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Fig. 4. Characteristic lesions in PSP immunostained with AT8 and
pS396, counterstained with TR. A) Tufted astrocytes. B) Intracel-
lular globose NFTs. C) Extracellular NFT. D) Pre-NFT positive for
antibody pT231 (green channel) in the apical soma and dendrite.
A dense spherical body was commonly observed in the neuronal
soma, reactive with both antibodies and TR. Scale bars, 10 m.
fibrillar aggregates in globose NFTs (gNFTs), where
there was colocalization of AT8/pS396 (Fig. 4B;
large arrow). A gNFT population also showed that
some aggregates were TR-positive (Fig. 4B; small
arrow); others showed a complete absence of AT8-
immunoreactivity. In Fig. 4C, pS396-positive NFTs
characterized by a loose fibrillar structure, showed
colocalizion with TR (Fig. 4C; arrow). Additionally,
a dense spherical structure was found continu-
ously within the neuronal bodies (Fig. 4D. Large
arrows). This structure reacted with all three mark-
ers (AT8/TR/pS396). However, some small fibrils,
positive only for the AT8 antibody (Fig. 4D; small
arrows), were observed in the apical neurite.
Tau aggregates in the neuronal soma in PSP
brain
NFTs, DNs, and neuropil threads are present in
both AD and PSP [19]. In PSP brains, several pat-
terns of aggregation and polymerization of the tau
protein in neuronal bodies were discernable. The
first tau aggregation pattern was seen using the AT8
antibody, which labeled a large number of small fib-
rils throughout the neuronal soma (Fig. 5A; arrows).
These fibrils were not recognized by either TR or
pS396 antibody. These fibrils were also labeled by
antibodies that recognize tau protein with intact N-
(499) and C-terminal (Tau7) region. In the second
aggregation pattern, small dense packets of tau were
immunoreactive for AT8, pS396, and TR (Fig. 5B;
arrows). Some fibrils, with the same characteristics
described in Fig. 5A, were observed in the neuronal
cytoplasm. DNs with similar staining characteristics
were found in this vicinity. The small NFTs tended
to elongate and fuse, invading the neuronal soma as
a trabecula (Fig. 5C; arrow), positive for all three
markers (AT8/TR/pS396). The aggregation process
for the formation of iNFTs is shown in Fig. 5D-F.
An immunoreactivity for markers AT8 and pS396,
partially colocalized with TR, was observed. In the
iNFTs, the TR staining was predominant and compact
(Fig. 5F; arrows). The eNFTs were characterized by
a loose fibrillar structure with scattered bundles of
filaments (Fig. 5G; arrows). This fibrillar structure
was labeled largely with TR and showed colocaliza-
tion with pS396 only in discrete areas. AT8-positive
DNs with varying degrees of TR colocalization were
noticed in the periphery.
Tufted astrocytes
The following patterns of immunoreactivity were
observed for TAs (Fig. 6). Individual glial cells and
pairs of glial cells were observed (Fig. 6A; arrows).
These cells were immunoreactive for both AT8 and
pS396 antibodies, and showed a high affinity for TR.
As the number of glial cells increased, a central space
appeared (Fig. 6B; arrows). Glial cell aggregates of
different sizes (Fig. 6C; arrows) formed the patho-
logical TAs (Fig. 6D; arrows). These glial cells were
TR-positive (Fig. 6D; small arrow).
Molecular processing of tau in PSP
Intact tau protein
The presence of N-terminal tau in pre-NFTs,
iNFTs, and TAs was demonstrated by an intermedi-
ate level of reactivity with the antibody 499 (Table 4).
However, the C-terminal region of tau protein, rec-
ognized by the Tau7 antibody, was present only
infrequently in the pre-NFTs and iNFTs (Table 4).
Tau7-negative and TR-positive TAs were observed.
Phosphorylation of the N-terminal region of tau
The antibodies that recognize the phosphoryla-
tion sites at pT231 (Fig. 7A-C), pS202 and pT205
(AT8; Fig. 7D-F) in the tau N-terminal region, showed
strong reactivity for pre-NFTs (Fig. 7; A++, D++)
and iNFTs (Fig. 7B+++, E++). In Fig. 7A and D,
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Fig. 5. Aggregation pattern of tau in the neuronal soma in PSP. Double immunostaining with AT8 and pS396 antibodies, counterstained
with TR. A) Pre-NFT labeled with AT8 antibody (arrows). Tau was aggregated as small fibrils that invade the neuronal soma completely. A
large number of dystrophic neurites and neuropil threads were noticed, which colocalize with TR and are recognized by the pS396 antibody.
B) Small NFTs. Both antibodies recognized small dense bundles of tau that invade the neuronal soma and apical dendrite. C) The small
NFTs showed a tendency to fuse, forming an intracellular trabecula and invading the neuronal soma. In these, the three markers colocalized
(arrows). D) Another common aggregation pattern observed was bundles of filaments recognized by TR colocalizing with both antibodies
to various extents (arrows). E,F) Intracellular NFTs showed a tendency to fill the neuronal body with highly insoluble filaments. G) Finally,
extracellular NFTs (eNFTs) were observed. The eNFTs were characterized by loosely packed fibers, recognized by the pS396 antibody and
TR. In the periphery, dystrophic neurites immunoreactive only with AT8 (green channel) were found. Scale bars, 10 m.
preNFT with small fibers distributed in the neuronal
soma (arrows) were observed. Both antibodies pT231
and AT8 showed immunoreactivity in various NFT
populations at different stages of neurodegeneration
(Fig. 7B, E). An NFT population appeared with a
compact and dense structure (Fig. 7E); another NFT
population showed a more flexible pattern. DNs were
observed in the vicinity (small arrow). TAs showed
a strong reactivity for both antibodies (Fig. 7C, F;
arrows).
Regional conformational changes
The conformational changes were investigated
using TG-3 (Fig. 7G-I) and AT100 (Fig. 7J-L). Quali-
tatively, the abundance of immunoreactive structures
with both antibodies was limited. Moderate reactiv-
ity for TG-3 and AT100 was observed in preNFTs
(Fig. 7G+, J+), iNFTs (Fig. 7H+, K+), and TAs
(Fig. 7I+, K+), and with the same characteristics pre-
viously described.
Structural conformational changes
The structural conformational changes recognized
by the antibody Alz50 recognizes tau with its N-
terminal portion intact. The Alz50-immunoreactivity
in preNFTs showed small fibrils (Fig 7M, O; arrows).
The reactivity in preNFTs and iNFTs was moder-
ate (++). This staining did not recognize the entire
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Fig. 6. Different tau expression patterns in tufted astrocytes (TAs)
in PSP. TAs were strongly recognized by AT8 and pS396 and
colocalized with TR. Scale bars, 10 m.
structure of the iNFTs (Fig. 7N; arrows). TAs were
strongly reactive with Alz50 (+++, Fig. 7R; arrows).
Phosphorylation of the C-terminal region of tau
The antibodies pS396 (Fig. 7P-R) and PHF1
(Fig. 7S-U) labeled preNFTs (Fig. 7P, S) and iNFTs
with moderate abundance (++, Fig. 7Q, T; arrows).
These antibodies reacted abundantly with the TAs
(+++). Additionally, the pS396 antibody evidenced
transitional NFTs, from iNFTs to eNFTs (Fig. 7Q;
arrow).
Extracellular neurofibrillary tangles
In AD, eNFTs are composed primarily of the
protease-resistant PHF-core comprised of a 92–95
amino acid fragment culminating at Glu391 and rec-
ognized by the 423 antibody. Truncation at Asp421,
generated by caspase-3, has been associated with the
early molecular stages of neurodegeneration in AD
[20]. Truncation at Asp421 and Glu391 favor the
polymerization of tau protein into highly insoluble
filaments.
Truncated tau
Tau truncated at Asp421 and Glu391 is recognized
by TauC-3 and 423, respectively. The iNFTs and
eNFTs in PSP were not detected with either of these
antibodies (Fig. 8A, C, respectively). These tangles
bound TR. In contrast, the TAs in PSP were labeled
by TR but not by Tau-C3 or 423.
Table 4
Qualitative expression of post-translational modifications of
pathological tau recognized by antibodies recognizing different
epitopes. This analysis is exclusive for PSP cases. C-terminal tau
protein (Tau-7 antibody) was detected weakly in the neurofibrillary
tangles (NFTs). However, the tufted astrocytes (TAs) showed no
positivity for this antibody. Phosphorylation at Thr231 not asso-
ciated with conformational change was abundant in NFTs and
TAs. There was no evidence of C-terminal truncation based on
absence of immunoreactivity with TauC–3 and 423. Thiazine red
(TR) recognized a population of NFTs and TAs
Antibody PreNFT iNFT Tufted
astrocytes
499 ++ ++ ++
TAU7 +/– +/– –
pT231 ++ +++ +++
AT8 ++ ++ +++
TG3 + + +
AT100 + + +
ALZ50 ++ ++ ++++
pS396 ++ ++ +++
PHF1 ++ ++ +++
499 ++ ++ –
423 – – –
TAU–C3 – + –
TR – ++ +++
DISCUSSION
PSP is a disorder with a very low prevalence and
that has been little studied to date. The histopatho-
logical lesions in PSP are NFTs and TAs [21]; with
the 4R-tau isoforms predominant in PSP [22]. Few
studies have focused on describing the morpholog-
ical development of tau pathology in this disorder.
A more in-depth analysis may favor a better under-
standing of the disease and the discovery of specific
markers for this and other tauopathies.
Aggregation of tau protein in NFT
In AD, the tau protein aggregation in the neu-
ronal body is characterized by the presence of diffuse
granular staining and various stages of NFT devel-
opment [23]. Tau protein referred to as pre-NFT is
characterized by a diffuse granular distribution in
the cytoplasm and perinuclear region. Antibodies
directed against phosphorylated tau in these granu-
lar structures did not colocalize with TR [24, 25].
However, tau showed a strong immunoreactivity for
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Fig. 7. Expression of different tau epitopes in pre-NFT, iNFT, and tufted astrocytes in PSP. Left) A-C) pT231, D-F) AT8, G-I) TG3, J-L)
AT100, M-O) Alz50, P-R) pS396, and S-U) PHF1. Right) Schematic with the location of the tau epitopes. Although all antibodies have
affinity for the structures shown, the expression pattern was qualitatively different (see Table 4). Scale bars, 10 m.
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phosphorylated tau markers in the neuronal soma.
This pattern of immunoreactivity in AD differs from
that found in PSP. In PSP, the first stages of aggrega-
tion showed abundant individual fibrils throughout
the neuronal cytoplasm. TR did not bind to this
structure, indicating that such aggregates are solu-
ble [26, 27]. Later, dense aggregates were observed
in the neuronal soma in both AD and PSP cases in
our study. In the latter aggregates, a considerable
accumulation of tau was observed, that was colocal-
ized with TR, suggesting that these small bundles
contain fibrillar structures with a -folded conforma-
tion. These aggregates are similar in AD and PSP,
with small tangles that tend to elongate and fuse,
forming a trabecula of bundles of fibrillar structures,
eventually invading the neuronal soma (iNFT), until
tangles become extracellular [16, 23–25]. The eNFTs
are characterized by having a loose morphology and
being exposed to the extracellular space [16, 17, 24,
26, 28, 29].
Molecular processing of the tau protein
The pathological processing of tau is initiated by
the presence of a truncated tau fragment of 92–95
amino acids in AD [25]. It is the minimal paired heli-
cal filament core fragment (PHF-core) [30–32] with a
truncation at Glu391 [33], and which is recognized by
the antibody 423 [34]. Recent studies have suggested
that the PHF-core is an early initiating event of AD
pathology [20]. It has been shown that the C-terminal
region of tau is very susceptible to proteolysis [29,
35]. Caspase-3 can proteolyze tau at Asp421 and
Binder developed an antibody, TauC-3, that recog-
nizes this truncation [36]. In vitro studies have shown
that the presence of truncated tau favors its polymer-
ization [37–41]. In PSP, study of the expression of
tau with its intact C-terminus has not been studied. It
is the opposite of the situation found in AD. Whereas
the N- and C-terminal domains of full-length tau
are abundant in iNFTs in AD, we did not see the
C-terminus in PSP. This suggests that proteolytic pro-
cessing of the C-terminus is more accelerated in PSP.
Phospho-tau epitopes are abundant in both AD and
PSP [42]. In contrast, tau phosphorylated at Ser396,
that is abundantly observed in the first aggregation
stage in the neuronal soma in PSP, is not observed in
the pre-NFTs in AD [35]. The specific sequence of
tau phosphorylation (as detected using pT231, TG3,
AT8, and AT100 antibodies) may favor both con-
formational and regional changes (TG3 and AT100)
[43], and generate structural changes (Alz50) [24,
25, 44]. Phosphorylation of tau at Ser396 has been
associated with late events in tau processing [25].
Previous biochemical studies, using different anti-
bodies against phosphorylated tau (Thr181, Ser202,
Ser214, Ser396, and Ser422), showed bands at 72,
50/55, and 37 kDa. Bands at 60, 42, 33, and 29 kDa
were also observed. The different molecular weights
and antibody affinities are associated with the pro-
teolysis of tau [45]. In AD, bands at 75–60–65 kDa
corresponded to full-length, phosphorylated tau. The
45 and 12 kDa bands were compatible with trun-
cated forms at Asp421 and Glu391 (recognized by the
TauC-3 and 423 antibodies, respectively). It has been
described that the protein fragment corresponding
to the PHF-core forms straight and helical filaments
with a beta-folded conformation under physiological
conditions. It shares a macromolecular structure sim-
ilar to the purified filaments from the AD brains [46].
In our analysis, no immunoreactivity was observed
with the antibody 423. Truncation at Asp421 was
reported in occasional NFTs in PSP previously [45].
This suggests that truncation at Glu391 is not a fea-
ture of PSP, according to Binder [42]. Some eNFT
and glial cell populations, labeled only by TR, were
observed in PSP. TR has an affinity for fibrillar struc-
tures with beta-folded conformation. This suggests
that one of the main differences in tau processing
between tauopathies is the presence of additional
truncation sites that favor the tau polymerization and
insolubility. Further studies are required to verify
this hypothesis. Our results suggest that other forms
of truncated tau could act as differential markers
between tauopathies.
Processing and polymerization of tau in neuronal
and glial cells in PSP
Tau aggregation occurs with intact and variably
phosphorylated tau protein molecules. Truncated tau
expression favors polymerization. In Fig. 9, we sum-
marize the observations described in this work. The
pre-NFT stage (Fig. 9A, B) is characterized by the
aggregation of tau into small fibrils, in which TR has
no affinity. In AD, tau phosphorylated at Ser396 is
not observed in pre-NFTs (results not shown). iNFTs
are a massive aggregation of TR-related filaments
(Fig. 9C, D). Sporadically, presence of moderate lev-
els of tau truncated at Asp421 was observed in the
iNFTs. An eNFT population with a high affinity for
TR and partially immunoreactive to the antibody
pS396 was found (Fig. 9E; arrow, Fig. 9G). Tau aggre-
gation appears to be a much more accelerated process
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Fig. 8. Absence of tau truncation in PSP: A, B) TauC-3 and C, D)
423. Lesions labeled by TR: A) iNFT, C) eNFT, and in B, D) tufted
astrocytes. Scale bars, 10 m, except for (B), 20 m.
in TAs than in neuronal NFTs. Tau occurs as abundant
dense aggregates related to TR in the glial population.
Fibrillar TR-positive tau was observed (Fig. 9G, H,
I, J). This could be due to faster processing of tau
by glial cells; these cells are involved in degrada-
tion and their proteolytic enzymes could accelerate
tau proteolysis. However, no immunoreactivity of the
antibody 423 to Glu-391 truncation was observed in
neuronal or glial NFTs. As previously suggested, this
fragment is highly toxic and favors the tau polymer-
ization. The glial cell population showed a strong
affinity for TR. Therefore, this result suggests that
there could be variability in the truncation sites that
favor the polymerization of tau for different disorders
and there may be truncations that are both specific and
characteristic for PSP.
Clinical implications of the tau pathological
processing in AD and PSP
In AD, there is a clear clinicopathological correla-
tion between cognitive deterioration and the presence
of NFTs in the hippocampus. Braak and Braak
described a staging sequence for the appearance of
NFT in the entorhinal cortex and hippocampus [47].
Later studies showed the relationship between these
lesions and cognitive impairment in AD [48]. An
attempt has been made to correlate the presence of
NFTs and tau aggregation in glial cells with the clin-
ical evolution of PSP pathology. Zuzana Stejskalova
analyzed the alteration of the pyramidal motor sys-
tem for various types of PSP (probable, possible
or suggestive, PSP-Richarson PSP-Parkinsonism).
Although a greater burden of histopathological
lesions was observed in PSP-Richarson, a significant
correlation between clinical symptoms and pathol-
ogy was not found [49]. On the other hand, areas
of the pallido-nigro-Luysial axis have recently been
analyzed in different clinical subtypes of PSP. Tau in
NFTs and glial cells suggest that there are different
processes regarding the clinical course of the patient
and the distribution of these lesions in the specific
regions. The vulnerability of cell populations in dif-
ferent areas needs to be determined as does the spread
of tau. Pathological tau can be transmitted between
neurons in a prion-like manner, as suggested for other
neurodegenerative diseases [41].
In PSP-Richardson, NFT accumulation has been
observed initially in subcortical and brainstem nuclei.
Early oligodendroglial damage in the globus pallidus
and astroglial involvement in the striatum has been
found. Subsequently, tau in astroglial cells continues
in cortical areas, which precede the accumulation of
cortical and oligodendroglial NFTs. This continues
together in a temporal sequence from frontoparietal-
temporal to occipital cortex. In PSP, it has been
proposed that NFTs can be found in early affected
areas. This could be sought, through neuroimaging
studies, in preclinical forms to understand the earliest
pathogenic events [50].
The presence of tau in NFTs, glial and microglial
cells are considered as pathological structures. In
AD, NFTs are correlated with the clinical dete-
rioration of patients. However, although a greater
number of lesions have been evidenced in PSP com-
pared to AD, no correlation with abnormal tau has
been reported in PSP. In PSP, pathological structures
are the products of much earlier events, for exam-
ple, a sustained inflammatory activity of glial and
microglial cells. This inflammation is produced by
interleukins, cytokines, and abundant reactive oxy-
gen species, which affect the neuronal metabolism
and favor the pathological tau processing, including
hyperphosphorylation and truncation [51].
CONCLUSION
The molecular processing of phosphorylated tau
differs between PSP and AD. In this study, we
observed the proteolytic processing of the C-terminal
portion of tau in AD and PSP. The regional (TG3 and
AT100) and conformational (Alz-50) changes, using
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Fig. 9. Schematic representation of the tau aggregation process in neuronal and glial degeneration in PSP. A-G) Neuronal degeneration,
H-M) Glial degeneration. A) Neurofibrillary pre-tangle. B) Representation showing a staining of small fibrils positive to the AT8 and pS396
antibodies and distributed throughout the neuronal soma. C, D, F. Arrow) Representation of different tau aggregation events, positive for
TR and colocalizing to varying degrees with AT8 and pS396 antibodies. E, G) NFT populations were recognized by TR and partially by the
pS396 antibody. H, I, J, K) Tau aggregation pattern in glial cells, which colocalize to varying extents for AT8 and pS396 antibodies. L, M)
Glial cells were mostly TR-positive. Scale bars, 100 m.
specific markers, were described in PSP. Contrary to
AD, phosphorylation at Ser396 was observed in pre-
NFTs in PSP. The truncation event of tau may be
pivotal in finding specific and differential markers
for AD, PSP, and other tauopathies.
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